Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study.
Adductor spasticity in children with cerebral palsy (CP) impairs motor function and development. In a placebo-controlled, double-blind, randomized multicentre study, we evaluated the effects of botulinum toxin A(BTX-A) in 61 children (37 males, 24 females; mean age 6 years 1 month [SD 3y 1mo]) with CP (leg-dominated tetraparesis, n=39; tetraparesis, n=22; GMFCS level I, n=3; II, n=6; III, n=17; IV, n=29; V, n=6). Four weeks after treatment, a significant superiority of BTX-A was observed in the primary outcome measure (knee-knee distance 'fast catch', p=0.002), the Ashworth scale (p=0.001), and the Goal Attainment Scale (p=0.037).
Mall
Volker
V
Children's University Hospital, Freiburg University, Germany. mall@kikli.ukl.uni-freiburg.de
Heinen
Florian
F
Siebel
Andrea
A
Bertram
Christoph
C
Hafkemeyer
Ulrich
U
Wissel
Jörg
J
Berweck
Steffen
S
Haverkamp
Fritz
F
Nass
Günter
G
Döderlein
Leo
L
Breitbach-Faller
Nico
N
Schulte-Mattler
Wilhelm
W
Korinthenberg
Rudolf
R
D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects; D002547:Cerebral Palsy / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D006621:Hip Joint / Q000502:physiology; D006801:Humans; D007719:Knee Joint / Q000502:physiology; D008297:Male; D009128:Muscle Spasticity / Q000188:drug therapy; D009465:Neuromuscular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D010919:Placebos; D016896:Treatment Outcome
D009465:Neuromuscular Agents; D010919:Placebos; D019274:Botulinum Toxins, Type A